Lung Cancer

Naiyer Rizvi MD and Heather Wakelee MD review data from key lung cancer presentations from the 2015 clinical oncology meeting in Chicago.

Share

Program Content

Activities

  • CheckMate 057
    CheckMate 057: Nivolumab Superior to Docetaxel in Previously Treated Advanced Nonsquamous NSCLC
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: May 31, 2015

    Expires: May 29, 2016

  • CheckMate 017
    CheckMate 017: Nivolumab Superior to Docetaxel in Previously Treated Advanced Squamous NSCLC
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: June 01, 2015

    Expires: May 30, 2016

  • First-Line AZD9291 in EGFR- Mutant NSCLC
    AURA: AZD9291 Active and Safe in Untreated EGFR Mutation–Positive Advanced NSCLC
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: June 01, 2015

    Expires: May 30, 2016

  • Pembrolizumab in SCLC
    KEYNOTE-028: Antitumor Activity With Pembrolizumab in Patients With PD-L1-Positive Extensive-Stage SCLC
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: June 01, 2015

    Expires: May 30, 2016

  • MAPS: Bevacizumab in MPM
    MAPS: Adding Bevacizumab to Pemetrexed/Cisplatin Increases Survival in Patients With Malignant Pleural Mesothelioma
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: June 02, 2015

    Expires: May 31, 2016

  • Rociletinib in EGFR Mutant NSCLC
    TIGER-X: Rociletinib Activity in EGFR T790M Mutant NSCLC
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: June 02, 2015

    Expires: May 31, 2016

  • POPLAR: Atezolizumab in NSCLC
    POPLAR: Atezolizumab Improved Survival vs Docetaxel in Patients With Advanced NSCLC and Increasing Levels of PD-L1 Expression
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: June 02, 2015

    Expires: May 31, 2016

  • KEYNOTE-021 NSCLC
    KEYNOTE-021: Pembrolizumab + Ipilimumab Active in Previously Treated Advanced NSCLC
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: June 02, 2015

    Expires: May 31, 2016

  • Dabrafenib/trametinib in BRAF+ NSCLC
    Dabrafenib + Trametinib Demonstrated Promising Activity in Pretreated BRAF V600E–Positive Advanced NSCLC
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: June 03, 2015

    Expires: June 01, 2016

  • Downloadable Slideset
    Lung Cancer
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: August 07, 2015

    Expires: August 05, 2016

  • Nivolumab ± Ipilimumab in SCLC
    CheckMate 032: Nivolumab ± Ipilimumab With Promising Activity in Recurrent SCLC
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

Provided by

ProCE Banner

Supporters

AstraZeneca

Bayer Healthcare Pharma

Bristol Myers Squibb

Celgene

Genentech BioOncology

Incyte

Novartis Pharmaceuticals Corporation